AVITA Medical, Inc.

NasdaqCM:RCEL Stock Report

Market Cap: US$337.3m

AVITA Medical Past Earnings Performance

Past criteria checks 0/6

AVITA Medical's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 30.1% per year.

Key information

-5.8%

Earnings growth rate

0.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate30.1%
Return on equity-468.8%
Net Margin-95.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Oct 04
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

AVITA Medical Is Interesting, But Not Just Yet

Dec 21

AVITA Medical reports preliminary Q2 revenue in-line with consensus

Jan 12

AVITA: COVID-19's Impact

Nov 17

Revenue & Expenses Breakdown

How AVITA Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:RCEL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2460-578822
30 Jun 2454-508021
31 Mar 2451-457221
31 Dec 2350-356621
30 Sep 2345-345917
30 Jun 2341-315317
31 Mar 2337-264815
31 Dec 2234-274514
30 Sep 2232-304415
30 Jun 2230-304314
31 Mar 2232-294115
31 Dec 2133-253816
30 Sep 2131-223415
30 Jun 2129-273715
31 Mar 2123-354213
31 Dec 2018-445011
30 Sep 2016-495411
30 Jun 2014-42499
31 Mar 2012-36438
31 Dec 1911-28357
30 Sep 198-23297
30 Jun 195-25288
31 Mar 194-22276
31 Dec 182-181710
30 Sep 181-151510
30 Jun 181-13166
31 Mar 181-12128
31 Dec 171-11127
30 Sep 171-10116
30 Jun 171-9115
31 Mar 171-8104
31 Dec 161-783
30 Sep 161-893
30 Jun 161-883
31 Mar 161-873
31 Dec 151-753
30 Sep 151-653
30 Jun 151-643
31 Mar 151-542
31 Dec 141-552
30 Sep 142-562
30 Jun 143-572
31 Mar 143-672
31 Dec 133-782

Quality Earnings: RCEL is currently unprofitable.

Growing Profit Margin: RCEL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RCEL is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.

Accelerating Growth: Unable to compare RCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: RCEL has a negative Return on Equity (-468.81%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies